Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial

William J. Sandborn, S. B. Hanauer, Seymour Katz et al. · Gastroenterology · 2001 · 911 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease

Jan M. H. van den Brande, Henri Braat, Gijs R. van den Brink et al. · Gastroenterology · 2003 · 725 citations · Full text

Life Sciences, Cell Biology, Immunology +16

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

Bernard J. Scallon · Cytokine · 1995 · 682 citations

Life Sciences, Immunology, Molecular Biology +12

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

Bernie Scallon, Ann Cai, Nancy Solowski et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 669 citations

Medicine, Immunology, Pharmacology +17

Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agents

Andrew Nesbitt, Gianluca Fossati, Marianne Bergin et al. · Inflammatory Bowel Diseases · 2007 · 473 citations

Veterinary Medicine, Immunology, Pharmacology +17